We use cookies to ensure that we give you the best experience on our website Learn more

Aug 30, 2018

Society of Hematologic Oncology Sixth Annual Meeting

21 / Double Hit Ph-Negative Adult B-ALL Patients with MYC and BCL2 Rearrangements and CDKN2A Genetic Abnormalities Have Poor Clinical Outcomes: Report of Two Cases

;

Chung;

Betty;

bchung@houstonmethodist.org;

Presenter;

Miller;

Tara;

tmiller@houstonmethodist.org;

Hao;

Suyang;

shao@houstonmethodist.org;

Zieske;

Arthur;

awzieske@houstonmethodist.org;

Ewton;

April;

aewton@houstonmethodist.org;

Zu;

Youli;

yzu@houstonmethodist.org;

Huh;

Yang;

yhuh@mdanderson.org;

Pingali;

Sai Ravi;

spingali@@houstonmethodist.org;

Iyer;

Swaminathan;

spiyer@mdanderson.org

double hit

b-all

myc

bcl-2

cdkn2a

Abstract

Abstract

thumbnail

Keywords

double hit

b-all

myc

bcl-2

cdkn2a

Abstract

Double Hit Ph-Negative B-ALL Patients with MYC and BCL2 Rearrangements and CDKN2A Genetic Abnormalities Have Poor Clinical Outcomes: Report of Two Cases CONTEXT: While much research has focused on the poorer prognosis of double/triple hit diffuse large B cell lymphoma patients, much less is known about the impact of concomitant MYC and BCL2 rearrangements on the outcomes of B-acute lymphoblastic leukemia (B-ALL) patients. DESIGN: Two rare cases of MYC+/BCL2+ double hit B-ALL were identified: one de novo and one likely dedifferentiated from a follicular lymphoma (FL). Clinical characteristics, lab findings, and outcomes were analyzed along with tissue evaluation and cytogenetic studies. Bone marrows were subjected to next-generation sequencing to identify gene mutations which may modify prognosis in these double hit acute leukemia patients. RESULTS: Patient 1 presented with high grade FL in a lymph node and bone marrow involvement by B-ALL and FL. Patient 2 was initially diagnosed with B-ALL in the bone marrow and a perirenal mass. Both were Philadelphia chromosome negative. Patient 1 initial FISH showed MYC+/BCL2+ double hit in the bone marrow while the lymph node only had t(14;18). Patient 2 had t(2;8) and homozygous t(14;18) in his marrow at relapse. Patient 2 achieved short-lived remission while patient 1 had a negative post-induction marrow but imaging consistent with extensive residual disease. Both had CDKN2A missense mutations at different exon 2 loci. Patient 1 also had CDKN2A deletion and KIT, ATRX, and STAG2 missense mutations post-induction and expired nine months post-diagnosis. Patient 2 expired at 6 months post-diagnosis. CONCLUSIONS: Double hit B-ALL is rare and may occur de novo or may dedifferentiate from a clonally related follicular lymphoma. Characterization of distinct features and outcomes of these patients is limited because fluorescence in situ hybridization (FISH) for MYC, BCL2, and/or BCL6 translocations are not generally performed for acute leukemia. Both patients were either refractory to or only experienced a short-lived remission with HyperCVAD induction. Both also were found to have CDKN2A copy number alterations which have been associated with adverse prognosis in B-ALL, independent of age, and passed away prior to 1 year from their initial diagnosis. Larger studies of double hit B-ALL patients are necessary to confirm the poorer prognosis of these patients and their need for more aggressive induction regimens than HyperCVAD.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.